DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity

ATM, ATR and DNA-PKcs kinases—the lessons from the mouse models: inhibition ≠ deletion

(2020) Demis Menolfi et al.   Cell and Bioscience

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity

(2020) Yonghan He et al.   Nature Communications

Senolytic compounds control a distinct fate of androgen receptor agonist- and antagonist-induced cellular senescent LNCaP prostate cancer cells

(2020) Thanakorn Pungsrinont et al.   Cell and Bioscience

L1 drives IFN in senescent cells and promotes age-associated inflammation

(2019) Marco De Cecco et al.   NATURE

Tumor Cell Escape from Therapy-Induced Senescence as a Model of Disease Recurrence after Dormancy

(2019) Tareq Saleh et al.   CANCER RESEARCH

Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence

(2019) Hubert Fleury et al.   Nature Communications

Drug Inducible CRISPR/Cas Systems

(2019) Jingfang Zhang et al.   Computational and Structural Biotechnology Journal

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer

(2019) Jacob J. Adashek et al.   Cells

Targeting senescent cells in translational medicine

(2019) Marta Paez‐Ribes et al.   EMBO Molecular Medicine

Inducing and exploiting vulnerabilities for the treatment of liver cancer

(2019) Cun Wang et al.   NATURE

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

(2019) Sajid Khan et al.   NATURE MEDICINE

The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression

(2018) Shadrielle Melijah G. Espiritu et al.   CELL

Regulation of cellular senescence via the FOXO4-p53 axis

(2018) Benjamin Bourgeois et al.   FEBS LETTERS

Cellular plasticity and the neuroendocrine phenotype in prostate cancer

(2018) Alastair H. Davies et al.   Nature Reviews Urology

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

(2018) Maha Hussain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad∆∆ through Bcl-2-dependent attenuation of autophagy

(2018) Carmen Aguirre-Hernández et al.   Oncogenesis

Managing Nonmetastatic Castration-resistant Prostate Cancer

(2018) Joaquin Mateo et al.   EUROPEAN UROLOGY

Genomic analysis of DNA repair genes and androgen signaling in prostate cancer

(2018) Kasey Jividen et al.   BMC CANCER

The Diagnosis and Treatment of Prostate Cancer

(2017) Mark S. Litwin et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Senescent cells: an emerging target for diseases of ageing

(2017) Bennett G. Childs et al.   NATURE REVIEWS DRUG DISCOVERY

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

(2017) Karim Fizazi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells

(2017) Maryam Ghashghaei et al.   PROSTATE

Cellular senescence drives age-dependent hepatic steatosis

(2017) Mikolaj Ogrodnik et al.   Nature Communications

Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy

(2017) Michael L. Blute et al.   PLoS One

A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC

(2017) Leleesha Samaraweera et al.   Scientific Reports

Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors

(2016) Yi Zhu et al.   AGING CELL

Keeping the senescence secretome under control: Molecular reins on the senescence-associated secretory phenotype

(2016) Nicolas Malaquin et al.   EXPERIMENTAL GERONTOLOGY

Weighing the Addition of Androgen Suppression Therapy to Radiotherapy Dose Escalation for Intermediate-Risk Prostate Cancer

(2016) Alan Pollack et al.   JOURNAL OF CLINICAL ONCOLOGY

Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075

(2016) Emily J. Faivre et al.   MOLECULAR CANCER RESEARCH

The Aging Epigenome

(2016) Lauren N. Booth et al.   MOLECULAR CELL

Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL

(2016) Reut Yosef et al.   Nature Communications

Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse

(2016) Marco Demaria et al.   Cancer Discovery

Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines

(2016) Jana Simova et al.   Oncotarget

IκB-Kinase-epsilon (IKKε) over-expression promotes the growth of prostate cancer through the C/EBP-β dependent activation of IL-6 gene expression

(2016) Benjamin Péant et al.   Oncotarget

MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8

(2016) Dipa Bhaumik et al.   Aging-US

Premature aging/senescence in cancer cells facing therapy: good or bad?

(2015) Llilians Calvo Gonzalez et al.   BIOGERONTOLOGY

PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions

(2015) Jonathan A Ledermann et al.   BRITISH JOURNAL OF CANCER

Long-term Safety and Antitumor Activity in the Phase 1–2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer

(2015) Celestia S. Higano et al.   EUROPEAN UROLOGY

A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia

(2015) Thomas J. Kipps et al.   LEUKEMIA & LYMPHOMA

Targeting the Mitotic Catastrophe Signaling Pathway in Cancer

(2015) Margaret M. Mc Gee   MEDIATORS OF INFLAMMATION

Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice

(2015) Jianhui Chang et al.   NATURE MEDICINE

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

(2015) Christopher J. Sweeney et al.   NEW ENGLAND JOURNAL OF MEDICINE

U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

(2015) Y.-M. Ning et al.   ONCOLOGIST

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

(2015) Joel D. Leverson et al.   Science Translational Medicine

BCL-2 is dispensable for thrombopoiesis and platelet survival

(2015) M A Debrincat et al.   Cell Death & Disease

DDR-mediated crosstalk between DNA-damaged cells and their microenvironment

(2015) Nicolas Malaquin et al.   Frontiers in Genetics

Androgen Depletion Induces Senescence in Prostate Cancer Cells through Down-regulation of Skp2

(2015) Zuzana Pernicová et al.   NEOPLASIA

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors

(2014) James M. Cleary et al.   INVESTIGATIONAL NEW DRUGS

The role of senescent cells in ageing

(2014) Jan M. van Deursen   NATURE

Small cell carcinoma of the prostate

(2014) Rosa Nadal et al.   Nature Reviews Urology

Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model

(2014) H G Nguyen et al.   ONCOGENE

Enhancing Chemotherapy Efficacy in Pten -Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity

(2014) Alberto Toso et al.   Cell Reports

Probing the depths of cellular senescence

(2013) Darren J. Baker et al.   JOURNAL OF CELL BIOLOGY

Synthetic lethal metabolic targeting of cellular senescence in cancer therapy

(2013) Jan R. Dörr et al.   NATURE

Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches

(2013) T Karantanos et al.   ONCOGENE

Androgen Deprivation-Induced Senescence Promotes Outgrowth of Androgen-Refractory Prostate Cancer Cells

(2013) Dominick G. A. Burton et al.   PLoS One

PARP Inhibition Sensitizes to Low Dose-Rate Radiation TMPRSS2-ERG Fusion Gene-Expressing and PTEN-Deficient Prostate Cancer Cells

(2013) Payel Chatterjee et al.   PLoS One

Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice

(2013) Sanjeev Shukla et al.   PROSTATE

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo

(2012) Jonathan A. Ewald et al.   PROSTATE

FOXO1 Inhibits Runx2 Transcriptional Activity and Prostate Cancer Cell Migration and Invasion

(2011) H. Zhang et al.   CANCER RESEARCH

Response of Human Prostate Cancer Cells and Tumors to Combining PARP Inhibition with Ionizing Radiation

(2011) J. C. Barreto-Andrade et al.   MOLECULAR CANCER THERAPEUTICS

PC3 is a cell line characteristic of prostatic small cell carcinoma

(2011) Sheng Tai et al.   PROSTATE

DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion

(2010) F. Rodier et al.   JOURNAL OF CELL SCIENCE

Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic

(2010) Dana V. Ferraris   JOURNAL OF MEDICINAL CHEMISTRY

Deregulation of FOXO3A during prostate cancer progression

(2009) Gupta   INTERNATIONAL JOURNAL OF ONCOLOGY

Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion

(2009) Francis Rodier et al.   NATURE CELL BIOLOGY

Drug-induced senescence bystander proliferation in prostate cancer cells in vitro and in vivo

(2008) J A Ewald et al.   BRITISH JOURNAL OF CANCER

Senescence-Associated Exosome Release from Human Prostate Cancer Cells

(2008) B. D. Lehmann et al.   CANCER RESEARCH

Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation

(2008) A. Seaton et al.   CARCINOGENESIS

Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor

(2008) Kamilla Malinowska et al.   ENDOCRINE-RELATED CANCER

Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor

(2008) Jean-Philippe Coppé et al.   PLOS BIOLOGY